{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T10:23:33Z","timestamp":1787826213223,"version":"build-2784847793"},"reference-count":168,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Health Labour Sciences Research Grant","award":["25KC1002"],"award-info":[{"award-number":["25KC1002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurochem Res"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s11064-026-04860-1","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T08:15:46Z","timestamp":1787818546000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Potential of Cannabidiol for the Treatment of Psychosis: Endocannabinoid Regulation of Serotonergic Neurotransmission via Serotonin 5-HT1A\/2A Receptors"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1765-8601","authenticated-orcid":false,"given":"Kazutoshi","family":"Yonemura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8951-7871","authenticated-orcid":false,"given":"Nobue","family":"Kitanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1266-7948","authenticated-orcid":false,"given":"Kazuo","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0822-4063","authenticated-orcid":false,"given":"F. Scott","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0691-0723","authenticated-orcid":false,"given":"Moe","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9509-5107","authenticated-orcid":false,"given":"Kento","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9147-396X","authenticated-orcid":false,"given":"Tomoaki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5632-2426","authenticated-orcid":false,"given":"George R.","family":"Uhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9938-8508","authenticated-orcid":false,"given":"Junichi","family":"Kitanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"4860_CR1","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1046\/j.1360-0443.1996.911115852.x","volume":"91","author":"IB Adams","year":"1996","unstructured":"Adams IB, Martin BR (1996) Cannabis: pharmacology and toxicology in animals and humans. Addiction 91:1585\u20131614","journal-title":"Addiction"},{"key":"4860_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-030-57369-0_1","volume":"1264","author":"EM Rock","year":"2021","unstructured":"Rock EM, Parker LA (2021) Constituents of Cannabis sativa. Adv Exp Med Biol 1264:1\u201313","journal-title":"Adv Exp Med Biol"},{"key":"4860_CR3","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/978-3-030-21737-2_8","volume":"1162","author":"MR Amin","year":"2019","unstructured":"Amin MR, Ali DW (2019) Pharmacology of medical cannabis. Adv Exp Med Biol 1162:151\u2013165","journal-title":"Adv Exp Med Biol"},{"key":"4860_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0009-3084(00)00184-5","volume":"108","author":"R Mechoulam","year":"2000","unstructured":"Mechoulam R, Hanu\u0161 L (2000) A historical overview of chemical research on cannabinoids. Chem Phys Lipids 108:1\u201313","journal-title":"Chem Phys Lipids"},{"key":"4860_CR5","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1021\/acs.chemrestox.5c00240","volume":"38","author":"CA Love","year":"2025","unstructured":"Love CA, Porter NA, Kim HH, Jaspers I (2025) Cannabinoid vaping products: regulation, composition, toxicological effects, and emerging research. Chem Res Toxicol 38:2028\u20132040","journal-title":"Chem Res Toxicol"},{"key":"4860_CR6","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.biopsych.2016.01.004","volume":"79","author":"MA ElSohly","year":"2016","unstructured":"ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC (2016) Changes in cannabis potency over the last 2 decades (1995\u20132014): analysis of current data in the United States. Biol Psychiatry 79:613\u2013619","journal-title":"Biol Psychiatry"},{"key":"4860_CR7","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.pbb.2005.01.026","volume":"81","author":"Z Justinova","year":"2005","unstructured":"Justinova Z, Goldberg SR, Heishman SJ, Tanda G (2005) Self-administration of cannabinoids by experimental animals and human marijuana smokers. Pharmacol Biochem Behav 81:285\u2013299","journal-title":"Pharmacol Biochem Behav"},{"key":"4860_CR8","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/sj.bjp.0702228","volume":"125","author":"DM Hutcheson","year":"1998","unstructured":"Hutcheson DM, Tzavara ET, Smadja C, Valjent E, Roques BP, Hanoune J, Maldonado R (1998) Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with delta-9-tetrahydrocannabinol. Br J Pharmacol 125:1567\u20131577","journal-title":"Br J Pharmacol"},{"key":"4860_CR9","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/S2215-0366(20)30290-X","volume":"7","author":"TP Freeman","year":"2020","unstructured":"Freeman TP, Hindocha C, Baio G, Shaban NDC, Thomas EM, Astbury D, Freeman AM, Lees R, Craft S, Morrison PD, Bloomfield MAP, O\u2019Ryan D, Kinghorn J, Morgan CJA, Mofeez A, Curran HV (2020) Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. Lancet Psychiatry 7:865\u2013874","journal-title":"Lancet Psychiatry"},{"key":"4860_CR10","doi-asserted-by":"publisher","first-page":"899221","DOI":"10.3389\/fpsyt.2022.899221","volume":"13","author":"G Cleirec","year":"2022","unstructured":"Cleirec G, Desmier E, Lacatus C, Lesgourgues S, Braun A, Peloso C, Obadia C (2022) Efficiency of inhaled Cannabidiol in cannabis use disorder: the pilot study Cannavap. Front Psychiatry 13:899221","journal-title":"Front Psychiatry"},{"key":"4860_CR11","doi-asserted-by":"publisher","first-page":"1322434","DOI":"10.3389\/fpsyt.2024.1322434","volume":"15","author":"DJ Heal","year":"2024","unstructured":"Heal DJ, Gosden J, Smith SL (2024) A critical assessment of the abuse, dependence and associated safety risks of naturally occurring and synthetic cannabinoids. Front Psychiatry 15:1322434","journal-title":"Front Psychiatry"},{"key":"4860_CR12","first-page":"1","volume":"71","author":"K \u010cerne","year":"2020","unstructured":"\u010cerne K (2020) Toxicological properties of \u03949-tetrahydrocannabinol and cannabidiol. Arh Hig Rada Toksikol 71:1\u201311","journal-title":"Arh Hig Rada Toksikol"},{"key":"4860_CR13","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/bs.apha.2021.10.006","volume":"93","author":"B Hempel","year":"2022","unstructured":"Hempel B, Xi ZX (2022) Receptor mechanisms underlying the CNS effects of cannabinoids: CB(1) receptor and beyond. Adv Pharmacol 93:275\u2013333","journal-title":"Adv Pharmacol"},{"key":"4860_CR14","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1111\/bph.13250","volume":"172","author":"RB Laprairie","year":"2015","unstructured":"Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM (2015) Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol 172:4790\u20134805","journal-title":"Br J Pharmacol"},{"key":"4860_CR15","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1001\/jama.2025.19433","volume":"335","author":"M Hsu","year":"2026","unstructured":"Hsu M, Shah A, Jordan A, Gold MS, Hill KP (2026) Therapeutic use of cannabis and cannabinoids: a review. JAMA 335:345\u2013359","journal-title":"JAMA"},{"key":"4860_CR16","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/epi.12631","volume":"55","author":"O Devinsky","year":"2014","unstructured":"Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C, Katz R, Di Marzo V, Jutras-Aswad D, Notcutt WG, Martinez-Orgado J, Robson PJ, Rohrback BG, Thiele E, Whalley B, Friedman D (2014) Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 55:791\u2013802","journal-title":"Epilepsia"},{"key":"4860_CR17","first-page":"319","volume-title":"International review of neurobiology","author":"RC Bri\u00e2nis","year":"2024","unstructured":"Bri\u00e2nis RC, Moreira FA, Iglesias LP (2024) Chapter thirteen - cannabidiol and addiction. In: Del-Bel E, Gomes FV, Lisboa SF (eds) International review of neurobiology. Academic Press, pp 319\u2013333"},{"key":"4860_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/adb.70047","volume":"30","author":"M Shafie","year":"2025","unstructured":"Shafie M, Ing K, Rostam-Abadi Y, Weleff J, Griffin M, Ranganathan M, Mohammad Aghaei A, Pratt N, Funaro MC, Bassir Nia A (2025) The potential use of cannabidiol in the treatment of opioid use disorder: a systematic review. Addict Biol 30:e70047","journal-title":"Addict Biol"},{"key":"4860_CR19","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1038\/s41386-025-02175-3","volume":"50","author":"E Chesney","year":"2025","unstructured":"Chesney E, Oliver D, Sarma A, Lamper AD, Slimani I, Lloyd M, Dickens AM, Welds M, Kr\u00e5kstr\u00f6m M, Gasparini-Andre I, Ore\u0161i\u010d M, Lawn W, Babayeva N, Freeman TP, Englund A, Strang J, McGuire P (2025) Does cannabidiol reduce the adverse effects of cannabis in schizophrenia? A randomised, double-blind, cross-over trial. Neuropsychopharmacology 50:1759\u20131767","journal-title":"Neuropsychopharmacology"},{"key":"4860_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.109074","volume":"212","author":"MB Borrego","year":"2022","unstructured":"Borrego MB, Chan AE, Ozburn AR (2022) Regulation of alcohol drinking by ventral striatum and extended amygdala circuitry. Neuropharmacology 212:109074","journal-title":"Neuropharmacology"},{"key":"4860_CR21","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1152\/physrev.00049.2021","volume":"104","author":"O Devinsky","year":"2024","unstructured":"Devinsky O, Jones NA, Cunningham MO, Jayasekera BAP, Devore S, Whalley BJ (2024) Cannabinoid treatments in epilepsy and seizure disorders. Physiol Rev 104:591\u2013649","journal-title":"Physiol Rev"},{"key":"4860_CR22","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/978-3-030-57369-0_7","volume":"1264","author":"V Golub","year":"2021","unstructured":"Golub V, Reddy DS (2021) Cannabidiol therapy for refractory epilepsy and seizure disorders. Adv Exp Med Biol 1264:93\u2013110","journal-title":"Adv Exp Med Biol"},{"key":"4860_CR23","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S0026-895X(25)09876-1","volume":"34","author":"WA Devane","year":"1988","unstructured":"Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34:605\u2013613","journal-title":"Mol Pharmacol"},{"key":"4860_CR24","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/346561a0","volume":"346","author":"LA Matsuda","year":"1990","unstructured":"Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561\u2013564","journal-title":"Nature"},{"key":"4860_CR25","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/365061a0","volume":"365","author":"S Munro","year":"1993","unstructured":"Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61\u201365","journal-title":"Nature"},{"issue":"Suppl 1","key":"4860_CR26","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1038\/sj.ijo.0803272","volume":"30","author":"RG Pertwee","year":"2006","unstructured":"Pertwee RG (2006) The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes (Lond) 30(Suppl 1):S13-18","journal-title":"Int J Obes (Lond)"},{"key":"4860_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/3-540-26573-2_2","author":"AC Howlett","year":"2005","unstructured":"Howlett AC (2005) Cannabinoid receptor signaling. Handb Exp Pharmacol. https:\/\/doi.org\/10.1007\/3-540-26573-2_2","journal-title":"Handb Exp Pharmacol"},{"key":"4860_CR28","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/nrn1247","volume":"4","author":"D Piomelli","year":"2003","unstructured":"Piomelli D (2003) The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4:873\u2013884","journal-title":"Nat Rev Neurosci"},{"key":"4860_CR29","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1006\/bbrc.2000.2686","volume":"271","author":"T Sugiura","year":"2000","unstructured":"Sugiura T, Yoshinaga N, Kondo S, Waku K, Ishima Y (2000) Generation of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, in picrotoxinin-administered rat brain. Biochem Biophys Res Commun 271:654\u2013658","journal-title":"Biochem Biophys Res Commun"},{"key":"4860_CR30","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/jb\/mvm070","volume":"141","author":"S Oka","year":"2007","unstructured":"Oka S, Arai S, Waku K, Tokumura A, Sugiura T (2007) Depolarization-induced rapid generation of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, in rat brain synaptosomes. J Biochem 141:687\u2013697","journal-title":"J Biochem"},{"key":"4860_CR31","doi-asserted-by":"publisher","first-page":"6826","DOI":"10.1523\/JNEUROSCI.0945-05.2005","volume":"25","author":"T Maejima","year":"2005","unstructured":"Maejima T, Oka S, Hashimotodani Y, Ohno-Shosaku T, Aiba A, Wu D, Waku K, Sugiura T, Kano M (2005) Synaptically driven endocannabinoid release requires Ca2+-assisted metabotropic glutamate receptor subtype 1 to phospholipase Cbeta4 signaling cascade in the cerebellum. J Neurosci 25:6826\u20136835","journal-title":"J Neurosci"},{"key":"4860_CR32","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/978-3-540-74805-2_14","volume":"184","author":"DM Lovinger","year":"2008","unstructured":"Lovinger DM (2008) Presynaptic modulation by endocannabinoids. Handb Exp Pharmacol 184:435\u2013477","journal-title":"Handb Exp Pharmacol"},{"key":"4860_CR33","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1177\/1073858406296716","volume":"13","author":"Y Hashimotodani","year":"2007","unstructured":"Hashimotodani Y, Ohno-Shosaku T, Kano M (2007) Endocannabinoids and synaptic function in the CNS. Neuroscientist 13:127\u2013137","journal-title":"Neuroscientist"},{"key":"4860_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00744","volume":"8","author":"E Mart\u00ednez-Pinilla","year":"2017","unstructured":"Mart\u00ednez-Pinilla E, Varani K, Reyes-Resina I, Angelats E, Vincenzi F, Ferreiro-Vera C, Oyarzabal J, Canela EI, Lanciego JL, Nadal X, Navarro G, Borea PA, Franco R (2017) Binding and signaling studies disclose a potential allosteric site for cannabidiol in cannabinoid CB(2) receptors. Front Pharmacol 8:744","journal-title":"Front Pharmacol"},{"key":"4860_CR35","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1615\/CritRevNeurobiol.v15.i2.10","volume":"15","author":"LJ Sim-Selley","year":"2003","unstructured":"Sim-Selley LJ (2003) Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Crit Rev Neurobiol 15:91\u2013119","journal-title":"Crit Rev Neurobiol"},{"key":"4860_CR36","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.brainres.2005.11.035","volume":"1071","author":"JP Gong","year":"2006","unstructured":"Gong JP, Onaivi ES, Ishiguro H, Liu QR, Tagliaferro PA, Brusco A, Uhl GR (2006) Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res 1071:10\u201323","journal-title":"Brain Res"},{"key":"4860_CR37","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/bcpt.13710","volume":"130","author":"J Peng","year":"2022","unstructured":"Peng J, Fan M, An C, Ni F, Huang W, Luo J (2022) A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD). Basic Clin Pharmacol Toxicol 130:439\u2013456","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"4860_CR38","first-page":"616","volume":"6","author":"E Zamberletti","year":"2021","unstructured":"Zamberletti E, Rubino T (2021) Impact of endocannabinoid system manipulation on neurodevelopmental processes relevant to schizophrenia. Biol Psychiatry Cogn Neurosci Neuroimaging 6:616\u2013626","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"4860_CR39","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/sj.bjp.0707460","volume":"152","author":"E Ryberg","year":"2007","unstructured":"Ryberg E, Larsson N, Sj\u00f6gren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T, Greasley PJ (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152:1092\u20131101","journal-title":"Br J Pharmacol"},{"key":"4860_CR40","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/sj.bjp.0707464","volume":"152","author":"RG Pertwee","year":"2007","unstructured":"Pertwee RG (2007) GPR55: a new member of the cannabinoid receptor clan? Br J Pharmacol 152:984\u2013986","journal-title":"Br J Pharmacol"},{"key":"4860_CR41","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.neuropharm.2017.08.017","volume":"125","author":"M Celorrio","year":"2017","unstructured":"Celorrio M, Rojo-Bustamante E, Fern\u00e1ndez-Su\u00e1rez D, S\u00e1ez E, Estella-Hermoso de Mendoza A, M\u00fcller CE, Ram\u00edrez MJ, Oyarz\u00e1bal J, Franco R, Aymerich MS (2017) GPR55: a therapeutic target for Parkinson\u2019s disease? Neuropharmacology 125:319\u2013332","journal-title":"Neuropharmacology"},{"key":"4860_CR42","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1038\/sj.bjp.0707419","volume":"152","author":"DG Johns","year":"2007","unstructured":"Johns DG, Behm DJ, Walker DJ, Ao Z, Shapland EM, Daniels DA, Riddick M, Dowell S, Staton PC, Green P, Shabon U, Bao W, Aiyar N, Yue TL, Brown AJ, Morrison AD, Douglas SA (2007) The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br J Pharmacol 152:825\u2013831","journal-title":"Br J Pharmacol"},{"key":"4860_CR43","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1210\/me.2011-1197","volume":"25","author":"CM Henstridge","year":"2011","unstructured":"Henstridge CM, Balenga NAB, Kargl J, Andradas C, Brown AJ, Irving A, Sanchez C, Waldhoer M (2011) Minireview: recent developments in the physiology and pathology of the lysophosphatidylinositol-sensitive receptor GPR55. Mol Endocrinol 25:1835\u20131848","journal-title":"Mol Endocrinol"},{"key":"4860_CR44","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.bbrc.2007.08.078","volume":"362","author":"S Oka","year":"2007","unstructured":"Oka S, Nakajima K, Yamashita A, Kishimoto S, Sugiura T (2007) Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem Biophys Res Commun 362:928\u2013934","journal-title":"Biochem Biophys Res Commun"},{"key":"4860_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1585181","volume":"16","author":"H Chen","year":"2025","unstructured":"Chen H, Li G, Deng L, Xu N, Lee SM, Nie X, Bian JS (2025) Identification and evaluation of a pinocembrin analog as a TRPV1 inhibitor with analgesic properties in murine pain models. Front Pharmacol 16:1585181","journal-title":"Front Pharmacol"},{"key":"4860_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceca.2024.102912","volume":"121","author":"Y Takayama","year":"2024","unstructured":"Takayama Y, Tominaga M (2024) Interaction between TRP channels and anoctamins. Cell Calcium 121:102912","journal-title":"Cell Calcium"},{"key":"4860_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0207198","volume":"13","author":"KA Best","year":"2018","unstructured":"Best KA, Bone DB, Vilas G, Gros R, Hammond JR (2018) Changes in aortic reactivity associated with the loss of equilibrative nucleoside transporter 1 (ENT1) in mice. PLoS ONE 13:e0207198","journal-title":"PLoS ONE"},{"key":"4860_CR48","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1089\/can.2019.0028","volume":"5","author":"RA Gray","year":"2020","unstructured":"Gray RA, Stott CG, Jones NA, Di Marzo V, Whalley BJ (2020) Anticonvulsive properties of cannabidiol in a model of generalized seizure are transient receptor potential vanilloid 1 dependent. Cannabis Cannabinoid Res 5:145\u2013149","journal-title":"Cannabis Cannabinoid Res"},{"key":"4860_CR49","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1684\/epd.2020.1135","volume":"22","author":"RA Gray","year":"2020","unstructured":"Gray RA, Whalley BJ (2020) The proposed mechanisms of action of CBD in epilepsy. Epileptic Disord 22:10\u201315","journal-title":"Epileptic Disord"},{"key":"4860_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26175354","author":"TM Stollenwerk","year":"2021","unstructured":"Stollenwerk TM, Pollock S, Hillard CJ (2021) Contribution of the adenosine 2A receptor to behavioral effects of tetrahydrocannabinol, cannabidiol and PECS-101. Molecules. https:\/\/doi.org\/10.3390\/molecules26175354","journal-title":"Molecules"},{"key":"4860_CR51","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.yebeh.2016.11.016","volume":"70","author":"TE Gaston","year":"2017","unstructured":"Gaston TE, Friedman D (2017) Pharmacology of cannabinoids in the treatment of epilepsy. Epilepsy Behav 70:313\u2013318","journal-title":"Epilepsy Behav"},{"key":"4860_CR52","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1159\/000521683","volume":"107","author":"CA Legare","year":"2022","unstructured":"Legare CA, Raup-Konsavage WM, Vrana KE (2022) Therapeutic potential of cannabis, cannabidiol, and cannabinoid-based pharmaceuticals. Pharmacology 107:131\u2013149","journal-title":"Pharmacology"},{"key":"4860_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-026-03533-3","author":"S Zhang","year":"2026","unstructured":"Zhang S, Chen Y, Zhang L, Yang X, Dong J, Lu M, Zhou N, Feng Y, Zhang Y, Zhou Y (2026) Global lifetime prevalence of schizophrenia: a systematic review and meta-analysis. Mol Psychiatry. https:\/\/doi.org\/10.1038\/s41380-026-03533-3","journal-title":"Mol Psychiatry"},{"key":"4860_CR54","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/wps.20693","volume":"19","author":"RA McCutcheon","year":"2020","unstructured":"McCutcheon RA, Krystal JH, Howes OD (2020) Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. World Psychiatry 19:15\u201333","journal-title":"World Psychiatry"},{"key":"4860_CR55","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3389\/fpsyt.2017.00118","volume":"8","author":"JC de Jonge","year":"2017","unstructured":"de Jonge JC, Vinkers CH, Hulshoff Pol HE, Marsman A (2017) GABAergic mechanisms in schizophrenia: linking postmortem and in vivo studies. Front Psychiatry 8:118","journal-title":"Front Psychiatry"},{"key":"4860_CR56","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1007\/s00702-019-02080-2","volume":"126","author":"SJ Kaar","year":"2019","unstructured":"Kaar SJ, Angelescu I, Marques TR, Howes OD (2019) Pre-frontal parvalbumin interneurons in schizophrenia: a meta-analysis of post-mortem studies. J Neural Transm 126:1637\u20131651","journal-title":"J Neural Transm"},{"key":"4860_CR57","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0165-1781(02)00036-7","volume":"110","author":"AM Cameron","year":"2002","unstructured":"Cameron AM, Oram J, Geffen GM, Kavanagh DJ, McGrath JJ, Geffen LB (2002) Working memory correlates of three symptom clusters in schizophrenia. Psychiatry Res 110:49\u201361","journal-title":"Psychiatry Res"},{"key":"4860_CR58","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852924002244","volume":"30","author":"JM Meyer","year":"2024","unstructured":"Meyer JM (2024) How antipsychotics work in schizophrenia: a primer on mechanisms. CNS Spectr 30:e6","journal-title":"CNS Spectr"},{"key":"4860_CR59","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.19r13113","author":"S Kurose","year":"2020","unstructured":"Kurose S, Mimura Y, Uchida H, Takahata K, Kim E, Suzuki T, Mimura M, Takeuchi H (2020) Dissociation in pharmacokinetic attenuation between central dopamine D2 receptor occupancy and peripheral blood concentration of antipsychotics: a systematic review. J Clin Psychiatry. https:\/\/doi.org\/10.4088\/jcp.19r13113","journal-title":"J Clin Psychiatry"},{"key":"4860_CR60","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.neubiorev.2017.09.027","volume":"85","author":"D Amato","year":"2018","unstructured":"Amato D, Vernon AC, Papaleo F (2018) Dopamine, the antipsychotic molecule: a perspective on mechanisms underlying antipsychotic response variability. Neurosci Biobehav Rev 85:146\u2013159","journal-title":"Neurosci Biobehav Rev"},{"key":"4860_CR61","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/B978-0-12-397920-9.00001-9","volume":"109","author":"SS Pappas","year":"2014","unstructured":"Pappas SS, Leventhal DK, Albin RL, Dauer WT (2014) Mouse models of neurodevelopmental disease of the basal ganglia and associated circuits. Curr Top Dev Biol 109:97\u2013169","journal-title":"Curr Top Dev Biol"},{"key":"4860_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fnbeh.2022.928610","volume":"16","author":"RG Mair","year":"2022","unstructured":"Mair RG, Francoeur MJ, Krell EM, Gibson BM (2022) Where actions meet outcomes: medial prefrontal cortex, central thalamus, and the basal ganglia. Front Behav Neurosci 16:928610","journal-title":"Front Behav Neurosci"},{"key":"4860_CR63","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/j.1755-5949.2010.00222.x","volume":"17","author":"M Nord","year":"2011","unstructured":"Nord M, Farde L (2011) Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS Neurosci Ther 17:97\u2013103","journal-title":"CNS Neurosci Ther"},{"key":"4860_CR64","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.pscychresns.2006.05.009","volume":"148","author":"M Talvik","year":"2006","unstructured":"Talvik M, Nordstr\u00f6m AL, Okubo Y, Olsson H, Borg J, Halldin C, Farde L (2006) Dopamine D2 receptor binding in drug-na\u00efve patients with schizophrenia examined with raclopride-C11 and positron emission tomography. Psychiatry Res 148:165\u2013173","journal-title":"Psychiatry Res"},{"key":"4860_CR65","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1038\/s41380-023-02203-y","volume":"28","author":"S Siafis","year":"2023","unstructured":"Siafis S, Wu H, Wang D, Burschinski A, Nomura N, Takeuchi H, Schneider-Thoma J, Davis JM, Leucht S (2023) Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis. Mol Psychiatry 28:3267\u20133277","journal-title":"Mol Psychiatry"},{"key":"4860_CR66","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0257129","volume":"16","author":"T Ali","year":"2021","unstructured":"Ali T, Sisay M, Tariku M, Mekuria AN, Desalew A (2021) Antipsychotic-induced extrapyramidal side effects: a systematic review and meta-analysis of observational studies. PLoS ONE 16:e0257129","journal-title":"PLoS ONE"},{"key":"4860_CR67","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/JCP.0b013e318166c4d5","volume":"28","author":"K Gao","year":"2008","unstructured":"Gao K, Kemp DE, Ganocy SJ, Gajwani P, Xia G, Calabrese JR (2008) Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol 28:203\u2013209","journal-title":"J Clin Psychopharmacol"},{"key":"4860_CR68","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/JCP.0b013e3182214aad","volume":"31","author":"H Uchida","year":"2011","unstructured":"Uchida H, Takeuchi H, Graff-Guerrero A, Suzuki T, Watanabe K, Mamo DC (2011) Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis. J Clin Psychopharmacol 31:497\u2013502","journal-title":"J Clin Psychopharmacol"},{"issue":"Suppl 1","key":"4860_CR69","first-page":"1","volume":"19","author":"JW Newcomer","year":"2005","unstructured":"Newcomer JW (2005) Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19(Suppl 1):1\u201393","journal-title":"CNS Drugs"},{"key":"4860_CR70","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s40264-017-0543-0","volume":"40","author":"L Hirsch","year":"2017","unstructured":"Hirsch L, Yang J, Bresee L, Jette N, Patten S, Pringsheim T (2017) Second-generation antipsychotics and metabolic side effects: a systematic review of population-based studies. Drug Saf 40:771\u2013781","journal-title":"Drug Saf"},{"key":"4860_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2025.107727","volume":"216","author":"PM Moran","year":"2025","unstructured":"Moran PM, Granger KT (2025) IUPHAR review: moving beyond dopamine-based therapeutic strategies for schizophrenia. Pharmacol Res 216:107727","journal-title":"Pharmacol Res"},{"key":"4860_CR72","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.biopsych.2024.03.014","volume":"96","author":"SM Paul","year":"2024","unstructured":"Paul SM, Yohn SE, Brannan SK, Neugebauer NM, Breier A (2024) Muscarinic receptor activators as novel treatments for schizophrenia. Biol Psychiatry 96:627\u2013637","journal-title":"Biol Psychiatry"},{"key":"4860_CR73","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1111\/bph.16221","volume":"181","author":"Y Lu","year":"2024","unstructured":"Lu Y, Hatzipantelis CJ, Langmead CJ, Stewart GD (2024) Molecular insights into orphan G protein-coupled receptors relevant to schizophrenia. Br J Pharmacol 181:2095\u20132113","journal-title":"Br J Pharmacol"},{"key":"4860_CR74","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","volume":"175","author":"P McGuire","year":"2018","unstructured":"McGuire P, Robson P, Cubala WJ, Vasile D, Morrison PD, Barron R, Taylor A, Wright S (2018) Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatry 175:225\u2013231","journal-title":"Am J Psychiatry"},{"issue":"6","key":"4860_CR75","doi-asserted-by":"publisher","first-page":"pyaf045","DOI":"10.1093\/ijnp\/pyaf045","volume":"29","author":"N Sharma","year":"2025","unstructured":"Sharma N, Khatib MN, Roopashree R, Kaur M, Srivastava M, Barwal A, Prasad GVS, Rajput P, Mittal V, Shabil M, Kumar A, Bushi G, Mehta R, Satapathy P, Sah S (2025) Efficacy and safety of the muscarinic receptor agonist KarXT (Xanomeline-Trospium) in Schizophrenia: a systematic review, meta-analysis and bayesian sensitivity analysis. Int J Neuropsychopharmacol 29(6):pyaf045","journal-title":"Int J Neuropsychopharmacol"},{"key":"4860_CR76","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/978-94-017-8591-4_12","volume-title":"Anhedonia: a comprehensive handbook volume I: conceptual issues and neurobiological advances","author":"J Kitanaka","year":"2014","unstructured":"Kitanaka J, Kitanaka N, Hall FS, Uhl GR, Takemura M (2014) Anhedonia in mouse models of methamphetamine-induced drug seeking behavior. In: Ritsner MS (ed) Anhedonia: a comprehensive handbook volume I: conceptual issues and neurobiological advances. Springer Netherlands, Dordrecht, pp 279\u2013308"},{"key":"4860_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2025.110622","volume":"279","author":"M Fryc","year":"2025","unstructured":"Fryc M, Kluzik D, Czopek A, Jo\u0144czyk J, Zag\u00f3rska A (2025) Serotonin 2A (5-HT(2A)) receptor as evolving biological target: function, structure, ligands and role in the therapy of neuropsychiatric diseases. Neuropharmacology 279:110622","journal-title":"Neuropharmacology"},{"key":"4860_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2025.06.011","author":"RM Murray","year":"2025","unstructured":"Murray RM, Egerton A, Gao Y, Grace AA, Howes O, Jauhar S, Leucht S, Chen EYH, MacCabe JH, McCutcheon RA, Natesan S, Taylor D (2025) Why is clozapine uniquely effective in treatment-resistant schizophrenia? A review and proposal. Biol Psychiatry. https:\/\/doi.org\/10.1016\/j.biopsych.2025.06.011","journal-title":"Biol Psychiatry"},{"key":"4860_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmr.2025.100059","volume":"77","author":"BR Cummins","year":"2025","unstructured":"Cummins BR, Billac GB, Nichols DE, Nichols CD (2025) 5-HT(2A) receptors: pharmacology and functional selectivity. Pharmacol Rev 77:100059","journal-title":"Pharmacol Rev"},{"issue":"Suppl 1","key":"4860_CR80","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4088\/JCP.10075su1.02","volume":"72","author":"CU Correll","year":"2011","unstructured":"Correll CU (2011) What are we looking for in new antipsychotics? J Clin Psychiatry 72(Suppl 1):9\u201313","journal-title":"J Clin Psychiatry"},{"key":"4860_CR81","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26157253","author":"CL Kandilakis","year":"2025","unstructured":"Kandilakis CL, Papatheodoropoulos C (2025) Serotonin modulation of dorsoventral hippocampus in physiology and schizophrenia. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms26157253","journal-title":"Int J Mol Sci"},{"key":"4860_CR82","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.neuroscience.2004.09.026","volume":"130","author":"N Kitanaka","year":"2005","unstructured":"Kitanaka N, Kitanaka J, Takemura M (2005) Inhibition of methamphetamine-induced hyperlocomotion in mice by clorgyline, a monoamine oxidase-a inhibitor, through alteration of the 5-hydroxytryptamine turnover in the striatum. Neuroscience 130:295\u2013308","journal-title":"Neuroscience"},{"key":"4860_CR83","doi-asserted-by":"publisher","DOI":"10.1007\/s12264-025-01515-z","author":"C Cui","year":"2025","unstructured":"Cui C, Dou X, Cen P, Jin C, Wang J, Niu J, Xue C, Tian M, Zhang H, Zhong Y (2025) PET molecular imaging of the endocannabinoid system in psychiatric disorders. Neurosci Bull. https:\/\/doi.org\/10.1007\/s12264-025-01515-z","journal-title":"Neurosci Bull"},{"key":"4860_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainresbull.2024.111007","volume":"215","author":"J Huang","year":"2024","unstructured":"Huang J, Huang H, Liu M, Yang W, Wang H (2024) Involvement of the TRPV1 receptor and the endocannabinoid system in schizophrenia. Brain Res Bull 215:111007","journal-title":"Brain Res Bull"},{"key":"4860_CR85","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/bs.irn.2024.04.013","volume":"177","author":"D Fabris","year":"2024","unstructured":"Fabris D, Lisboa JR, Guimar\u00e3es FS, Gomes FV (2024) Cannabidiol as an antipsychotic drug. Int Rev Neurobiol 177:295\u2013317","journal-title":"Int Rev Neurobiol"},{"key":"4860_CR86","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/bs.irn.2024.05.001","volume":"177","author":"PHC Lirio","year":"2024","unstructured":"Lirio PHC, Gaspari PDM, Campos AC (2024) Cannabidiol: pharmacodynamics and pharmacokinetic in the context of neuropsychiatric disorders. Int Rev Neurobiol 177:11\u201327","journal-title":"Int Rev Neurobiol"},{"key":"4860_CR87","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.schres.2019.01.030","volume":"213","author":"FV Gomes","year":"2019","unstructured":"Gomes FV, Zhu X, Grace AA (2019) Stress during critical periods of development and risk for schizophrenia. Schizophr Res 213:107\u2013113","journal-title":"Schizophr Res"},{"key":"4860_CR88","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S2215-0366(20)30569-1","volume":"8","author":"V Warrier","year":"2021","unstructured":"Warrier V, Kwong ASF, Luo M, Dalvie S, Croft J, Sallis HM, Baldwin J, Munaf\u00f2 MR, Nievergelt CM, Grant AJ, Burgess S, Moore TM, Barzilay R, McIntosh A, van Ijzendoorn MH, Cecil CAM (2021) Gene\u2013environment correlations and causal effects of childhood maltreatment on physical and mental health: a genetically informed approach. Lancet Psychiatry 8:373\u2013386","journal-title":"Lancet Psychiatry"},{"key":"4860_CR89","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41398-021-01330-w","volume":"11","author":"M Wainberg","year":"2021","unstructured":"Wainberg M, Jacobs GR, di Forti M, Tripathy SJ (2021) Cannabis, schizophrenia genetic risk, and psychotic experiences: a cross-sectional study of 109,308 participants from the UK Biobank. Transl Psychiatry 11:211","journal-title":"Transl Psychiatry"},{"key":"4860_CR90","doi-asserted-by":"publisher","first-page":"19115","DOI":"10.1073\/pnas.0509494102","volume":"102","author":"P Berghuis","year":"2005","unstructured":"Berghuis P, Dobszay MB, Wang X, Spano S, Ledda F, Sousa KM, Schulte G, Ernfors P, Mackie K, Paratcha G, Hurd YL, Harkany T (2005) Endocannabinoids regulate interneuron migration and morphogenesis by transactivating the TrkB receptor. Proc Natl Acad Sci U S A 102:19115\u201319120","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4860_CR91","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/j.1460-9568.2010.07337.x","volume":"32","author":"CS Wu","year":"2010","unstructured":"Wu CS, Zhu J, Wager-Miller J, Wang S, O\u2019Leary D, Monory K, Lutz B, Mackie K, Lu HC (2010) Requirement of cannabinoid CB(1) receptors in cortical pyramidal neurons for appropriate development of corticothalamic and thalamocortical projections. Eur J Neurosci 32:693\u2013706","journal-title":"Eur J Neurosci"},{"key":"4860_CR92","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1098\/rstb.2011.0385","volume":"367","author":"J D\u00edaz-Alonso","year":"2012","unstructured":"D\u00edaz-Alonso J, Guzm\u00e1n M, Galve-Roperh I (2012) Endocannabinoids via CB\u2081 receptors act as neurogenic niche cues during cortical development. Philos Trans R Soc Lond B Biol Sci 367:3229\u20133241","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"4860_CR93","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1152\/physrev.00019.2008","volume":"89","author":"M Kano","year":"2009","unstructured":"Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M (2009) Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 89:309\u2013380","journal-title":"Physiol Rev"},{"key":"4860_CR94","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s002109900147","volume":"361","author":"M Nakazi","year":"2000","unstructured":"Nakazi M, Bauer U, Nickel T, Kathmann M, Schlicker E (2000) Inhibition of serotonin release in the mouse brain via presynaptic cannabinoid CB1 receptors. Naunyn Schmiedebergs Arch Pharmacol 361:19\u201324","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"4860_CR95","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.neuropharm.2012.06.003","volume":"63","author":"H Richter","year":"2012","unstructured":"Richter H, Teixeira FM, Ferreira SG, Kittel \u00c1, K\u00f6falvi A, Sperl\u00e1gh B (2012) Presynaptic \u03b12-adrenoceptors control the inhibitory action of presynaptic CB1 cannabinoid receptors on prefrontocortical norepinephrine release in the rat. Neuropharmacology 63:784\u2013797","journal-title":"Neuropharmacology"},{"key":"4860_CR96","doi-asserted-by":"publisher","DOI":"10.5402\/2012\/276902","volume":"2012","author":"R Tao","year":"2012","unstructured":"Tao R, Ma Z (2012) Neural circuit in the dorsal raphe nucleus responsible for cannabinoid-mediated increases in 5-HT efflux in the nucleus accumbens of the rat brain. ISRN Pharmacol 2012:276902","journal-title":"ISRN Pharmacol"},{"key":"4860_CR97","first-page":"234","volume":"35","author":"\u00d6 T\u00fcrko\u011flu","year":"2024","unstructured":"T\u00fcrko\u011flu \u00d6, Ertu\u011frul A (2024) The role of cannabis in the development of psychosis. Turk Psikiyatri Derg 35:234\u2013244","journal-title":"Turk Psikiyatri Derg"},{"key":"4860_CR98","volume":"17","author":"J Rajput","year":"2025","unstructured":"Rajput J, Narahari S, Arif T, Iftikhar R, Arpan T, Tariq A, Ali Duleh HM, Cherukuri SP (2025) The relationship between cannabis use and schizophrenia as a risk factor or for its therapeutic potential: a systematic review of evidence. Cureus 17:e92793","journal-title":"Cureus"},{"key":"4860_CR99","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.bpsgos.2022.01.008","volume":"3","author":"BC Ho","year":"2023","unstructured":"Ho BC, Barry AB, Koeppel JA, Macleod J, Boyd A, David A, O\u2019Leary DS (2023) Recreational marijuana use, adolescent cognitive development, and schizophrenia susceptibility. Biol Psychiatry Glob Open Sci 3:222\u2013232","journal-title":"Biol Psychiatry Glob Open Sci"},{"key":"4860_CR100","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S0014-2999(02)01755-7","volume":"445","author":"N Egashira","year":"2002","unstructured":"Egashira N, Mishima K, Katsurabayashi S, Yoshitake T, Matsumoto Y, Ishida J, Yamaguchi M, Iwasaki K, Fujiwara M (2002) Involvement of 5-hydroxytryptamine neuronal system in Delta(9)-tetrahydrocannabinol-induced impairment of spatial memory. Eur J Pharmacol 445:221\u2013229","journal-title":"Eur J Pharmacol"},{"key":"4860_CR101","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1017\/S0007114508083530","volume":"101","author":"I Merroun","year":"2009","unstructured":"Merroun I, Errami M, Hoddah H, Urbano G, Porres JM, Aranda P, Llopis J, L\u00f3pez-Jurado M (2009) Influence of intracerebroventricular or intraperitoneal administration of cannabinoid receptor agonist (WIN 55,212-2) and inverse agonist (AM 251) on the regulation of food intake and hypothalamic serotonin levels. Br J Nutr 101:1569\u20131578","journal-title":"Br J Nutr"},{"key":"4860_CR102","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.neuroscience.2007.10.026","volume":"151","author":"K Sano","year":"2008","unstructured":"Sano K, Mishima K, Koushi E, Orito K, Egashira N, Irie K, Takasaki K, Katsurabayashi S, Iwasaki K, Uchida N, Egawa T, Kitamura Y, Nishimura R, Fujiwara M (2008) Delta 9-tetrahydrocannabinol-induced catalepsy-like immobilization is mediated by decreased 5-HT neurotransmission in the nucleus accumbens due to the action of glutamate-containing neurons. Neuroscience 151:320\u2013328","journal-title":"Neuroscience"},{"key":"4860_CR103","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.neuint.2007.07.008","volume":"52","author":"T Bal\u00e1zsa","year":"2008","unstructured":"Bal\u00e1zsa T, B\u00edr\u00f3 J, Gullai N, Ledent C, Sperl\u00e1gh B (2008) CB1-cannabinoid receptors are involved in the modulation of non-synaptic [3H]serotonin release from the rat hippocampus. Neurochem Int 52:95\u2013102","journal-title":"Neurochem Int"},{"key":"4860_CR104","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.neuint.2012.05.009","volume":"61","author":"SG Ferreira","year":"2012","unstructured":"Ferreira SG, Teixeira FM, Gar\u00e7\u00e3o P, Agostinho P, Ledent C, Cortes L, Mackie K, K\u00f6falvi A (2012) Presynaptic CB(1) cannabinoid receptors control frontocortical serotonin and glutamate release\u2013species differences. Neurochem Int 61:219\u2013226","journal-title":"Neurochem Int"},{"key":"4860_CR105","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0091-3057(03)00150-3","volume":"75","author":"NA Darmani","year":"2003","unstructured":"Darmani NA, Janoyan JJ, Kumar N, Crim JL (2003) Behaviorally active doses of the CB1 receptor antagonist SR 141716A increase brain serotonin and dopamine levels and turnover. Pharmacol Biochem Behav 75:777\u2013787","journal-title":"Pharmacol Biochem Behav"},{"key":"4860_CR106","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/sj.bjp.0705100","volume":"138","author":"ET Tzavara","year":"2003","unstructured":"Tzavara ET, Davis RJ, Perry KW, Li X, Salhoff C, Bymaster FP, Witkin JM, Nomikos GG (2003) The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br J Pharmacol 138:544\u2013553","journal-title":"Br J Pharmacol"},{"key":"4860_CR107","doi-asserted-by":"publisher","first-page":"18620","DOI":"10.1073\/pnas.0509591102","volume":"102","author":"G Gobbi","year":"2005","unstructured":"Gobbi G, Bambico FR, Mangieri R, Bortolato M, Campolongo P, Solinas M, Cassano T, Morgese MG, Debonnel G, Duranti A, Tontini A, Tarzia G, Mor M, Trezza V, Goldberg SR, Cuomo V, Piomelli D (2005) Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci U S A 102:18620\u201318625","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4860_CR108","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2012.15","volume":"2","author":"FM Leweke","year":"2012","unstructured":"Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, Klosterk\u00f6tter J, Hellmich M, Koethe D (2012) Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2:e94","journal-title":"Transl Psychiatry"},{"key":"4860_CR109","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2016.00422","volume":"7","author":"C Rohleder","year":"2016","unstructured":"Rohleder C, M\u00fcller JK, Lange B, Leweke FM (2016) Cannabidiol as a potential new type of an antipsychotic. A critical review of the evidence. Front Pharmacol 7:422","journal-title":"Front Pharmacol"},{"key":"4860_CR110","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1111\/ejn.14407","volume":"50","author":"K Cohen","year":"2019","unstructured":"Cohen K, Weizman A, Weinstein A (2019) Modulatory effects of cannabinoids on brain neurotransmission. Eur J Neurosci 50:2322\u20132345","journal-title":"Eur J Neurosci"},{"key":"4860_CR111","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/501726","volume":"2011","author":"CM Coulston","year":"2011","unstructured":"Coulston CM, Perdices M, Henderson AF, Malhi GS (2011) Cannabinoids for the treatment of schizophrenia? A balanced neurochemical framework for both adverse and therapeutic effects of cannabis use. Schizophr Res Treatment 2011:501726","journal-title":"Schizophr Res Treatment"},{"key":"4860_CR112","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s00213-021-05801-2","volume":"239","author":"B Gunasekera","year":"2022","unstructured":"Gunasekera B, Diederen K, Bhattacharyya S (2022) Cannabinoids, reward processing, and psychosis. Psychopharmacology 239:1157\u20131177","journal-title":"Psychopharmacology"},{"key":"4860_CR113","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.lfs.2017.11.029","volume":"192","author":"A Mendiguren","year":"2018","unstructured":"Mendiguren A, Aostri E, Pineda J (2018) Regulation of noradrenergic and serotonergic systems by cannabinoids: relevance to cannabinoid-induced effects. Life Sci 192:115\u2013127","journal-title":"Life Sci"},{"key":"4860_CR114","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1111\/j.1471-4159.2009.06025.x","volume":"109","author":"E Aso","year":"2009","unstructured":"Aso E, Renoir T, Mengod G, Ledent C, Hamon M, Maldonado R, Lanfumey L, Valverde O (2009) Lack of CB1 receptor activity impairs serotonergic negative feedback. J Neurochem 109:935\u2013944","journal-title":"J Neurochem"},{"key":"4860_CR115","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.nbd.2009.11.020","volume":"37","author":"FR Bambico","year":"2010","unstructured":"Bambico FR, Nguyen NT, Katz N, Gobbi G (2010) Chronic exposure to cannabinoids during adolescence but not during adulthood impairs emotional behaviour and monoaminergic neurotransmission. Neurobiol Dis 37:641\u2013655","journal-title":"Neurobiol Dis"},{"key":"4860_CR116","doi-asserted-by":"publisher","first-page":"11700","DOI":"10.1523\/JNEUROSCI.1636-07.2007","volume":"27","author":"FR Bambico","year":"2007","unstructured":"Bambico FR, Katz N, Debonnel G, Gobbi G (2007) Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex. J Neurosci 27:11700\u201311711","journal-title":"J Neurosci"},{"key":"4860_CR117","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S0091-3057(00)00477-9","volume":"68","author":"NA Darmani","year":"2001","unstructured":"Darmani NA (2001) Cannabinoids of diverse structure inhibit two DOI-induced 5-HT(2A) receptor-mediated behaviors in mice. Pharmacol Biochem Behav 68:311\u2013317","journal-title":"Pharmacol Biochem Behav"},{"key":"4860_CR118","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1017\/S1461145705005651","volume":"9","author":"MN Hill","year":"2006","unstructured":"Hill MN, Sun JC, Tse MT, Gorzalka BB (2006) Altered responsiveness of serotonin receptor subtypes following long-term cannabinoid treatment. Int J Neuropsychopharmacol 9:277\u2013286","journal-title":"Int J Neuropsychopharmacol"},{"key":"4860_CR119","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.neulet.2013.05.039","volume":"548","author":"JM Franklin","year":"2013","unstructured":"Franklin JM, Mathew M, Carrasco GA (2013) Cannabinoid-induced upregulation of serotonin 2A receptors in the hypothalamic paraventricular nucleus and anxiety-like behaviors in rats. Neurosci Lett 548:165\u2013169","journal-title":"Neurosci Lett"},{"key":"4860_CR120","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1177\/0269881112450786","volume":"26","author":"JM Franklin","year":"2012","unstructured":"Franklin JM, Carrasco GA (2012) Cannabinoid-induced enhanced interaction and protein levels of serotonin 5-HT(2A) and dopamine D\u2082 receptors in rat prefrontal cortex. J Psychopharmacol 26:1333\u20131347","journal-title":"J Psychopharmacol"},{"key":"4860_CR121","doi-asserted-by":"publisher","first-page":"6347","DOI":"10.1007\/s12035-017-0833-7","volume":"55","author":"L Galindo","year":"2018","unstructured":"Galindo L, Moreno E, L\u00f3pez-Armenta F, Guinart D, Cuenca-Royo A, Izquierdo-Serra M, Xicota L, Fernandez C, Menoyo E, Fern\u00e1ndez-Fern\u00e1ndez JM, Ben\u00edtez-King G, Canela EI, Casad\u00f3 V, P\u00e9rez V, de la Torre R, Robledo P (2018) Cannabis users show enhanced expression of CB(1)-5HT(2A) receptor heteromers in olfactory neuroepithelium cells. Mol Neurobiol 55:6347\u20136361","journal-title":"Mol Neurobiol"},{"key":"4860_CR122","doi-asserted-by":"publisher","first-page":"21838","DOI":"10.1021\/acsomega.3c08934","volume":"9","author":"T Sun","year":"2024","unstructured":"Sun T, Du YY, Zhang YQ, Tian QQ, Li X, Yu JY, Guo YY, Liu QQ, Yang L, Wu YM, Yang Q, Zhao MG (2024) Activation of GPR55 ameliorates maternal separation-induced learning and memory deficits by augmenting 5-HT synthesis in the dorsal raphe nucleus of juvenile mice. ACS Omega 9:21838\u201321850","journal-title":"ACS Omega"},{"key":"4860_CR123","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.neuropharm.2015.12.017","volume":"103","author":"R Linge","year":"2016","unstructured":"Linge R, Jim\u00e9nez-S\u00e1nchez L, Campa L, Pilar-Cu\u00e9llar F, Vidal R, Pazos A, Adell A, D\u00edaz \u00c1 (2016) Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT\/glutamate neurotransmission: role of 5-HT1A receptors. Neuropharmacology 103:16\u201326","journal-title":"Neuropharmacology"},{"key":"4860_CR124","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1001\/jamapsychiatry.2025.3430","volume":"83","author":"M Osugo","year":"2026","unstructured":"Osugo M, Whitehurst T, Erritzoe D, Carr R, Ashok AH, Maccioni L, Onwordi EC, Rutigliano G, Rahaman N, Arumuham A, de Marvao A, Gunn RN, Rabiner EA, Marques TR, Veronese M, Howes OD (2026) Role of serotonin in the neurobiology of schizophrenia and association with negative symptoms. JAMA Psychiat 83:185\u2013195","journal-title":"JAMA Psychiat"},{"key":"4860_CR125","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1017\/S0033291719003532","volume":"51","author":"C Hjorth\u00f8j","year":"2021","unstructured":"Hjorth\u00f8j C, Larsen MO, Starzer MSK, Nordentoft M (2021) Annual incidence of cannabis-induced psychosis, other substance-induced psychoses and dually diagnosed schizophrenia and cannabis use disorder in Denmark from 1994 to 2016. Psychol Med 51:617\u2013622","journal-title":"Psychol Med"},{"key":"4860_CR126","doi-asserted-by":"publisher","DOI":"10.3390\/biom15030368","author":"S Pourebrahim","year":"2025","unstructured":"Pourebrahim S, Ahmad T, Rottmann E, Schulze J, Scheller B (2025) Does cannabis use contribute to schizophrenia? A causation analysis based on epidemiological evidence. Biomolecules. https:\/\/doi.org\/10.3390\/biom15030368","journal-title":"Biomolecules"},{"key":"4860_CR127","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1089\/can.2023.0032","volume":"9","author":"E Chesney","year":"2024","unstructured":"Chesney E, Lawn W, McGuire P (2024) Assessing cannabis use in people with psychosis. Cannabis Cannabinoid Res 9:49\u201358","journal-title":"Cannabis Cannabinoid Res"},{"key":"4860_CR128","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.1098\/rstb.2011.0389","volume":"367","author":"AC Campos","year":"2012","unstructured":"Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimar\u00e3es FS (2012) Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci 367:3364\u20133378","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"4860_CR129","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/nyas.14413","volume":"1475","author":"E Mart\u00ednez-Pinilla","year":"2020","unstructured":"Mart\u00ednez-Pinilla E, Rico AJ, Rivas-Santisteban R, Lillo J, Roda E, Navarro G, Franco R, Lanciego JL (2020) Expression of cannabinoid CB(1) R-GPR55 heteromers in neuronal subtypes of the Macaca fascicularis striatum. Ann N Y Acad Sci 1475:34\u201342","journal-title":"Ann N Y Acad Sci"},{"key":"4860_CR130","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1007\/s00429-020-02116-4","volume":"225","author":"E Mart\u00ednez-Pinilla","year":"2020","unstructured":"Mart\u00ednez-Pinilla E, Rico AJ, Rivas-Santisteban R, Lillo J, Roda E, Navarro G, Lanciego JL, Franco R (2020) Expression of GPR55 and either cannabinoid CB(1) or CB(2) heteroreceptor complexes in the caudate, putamen, and accumbens nuclei of control, parkinsonian, and dyskinetic non-human primates. Brain Struct Funct 225:2153\u20132164","journal-title":"Brain Struct Funct"},{"key":"4860_CR131","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0169-328X(98)00277-0","volume":"64","author":"M Sawzdargo","year":"1999","unstructured":"Sawzdargo M, Nguyen T, Lee DK, Lynch KR, Cheng R, Heng HHQ, George SR, O\u2019Dowd BF (1999) Identification and cloning of three novel human G protein-coupled receptor genes GPR52, \u03a8GPR53 and GPR55: GPR55 is extensively expressed in human brain1Sequence data from this article have been deposited with the GenBank Data Library under Accession Nos. AF096784-AF096786, AF100789.1. Mol Brain Res 64:193\u2013198","journal-title":"Mol Brain Res"},{"key":"4860_CR132","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.expneurol.2014.06.017","volume":"261","author":"E Mart\u00ednez-Pinilla","year":"2014","unstructured":"Mart\u00ednez-Pinilla E, Reyes-Resina I, O\u00f1atibia-Astibia A, Zamarbide M, Ricobaraza A, Navarro G, Moreno E, Dopeso-Reyes IG, Sierra S, Rico AJ, Roda E, Lanciego JL, Franco R (2014) CB1 and GPR55 receptors are co-expressed and form heteromers in rat and monkey striatum. Exp Neurol 261:44\u201352","journal-title":"Exp Neurol"},{"key":"4860_CR133","doi-asserted-by":"publisher","first-page":"771","DOI":"10.2174\/1570159X14666160729155441","volume":"15","author":"BA Marichal-Cancino","year":"2017","unstructured":"Marichal-Cancino BA, Fajardo-Valdez A, Ruiz-Contreras AE, Mendez-D\u00edaz M, Prospero-Garc\u00eda O (2017) Advances in the physiology of GPR55 in the central nervous system. Curr Neuropharmacol 15:771\u2013778","journal-title":"Curr Neuropharmacol"},{"key":"4860_CR134","doi-asserted-by":"publisher","first-page":"4","DOI":"10.5603\/PJNNS.a2022.0015","volume":"56","author":"M \u015amiarowska","year":"2022","unstructured":"\u015amiarowska M, Bia\u0142ecka M, Machoy-Mokrzy\u0144ska A (2022) Cannabis and cannabinoids: pharmacology and therapeutic potential. Neurol Neurochir Pol 56:4\u201313","journal-title":"Neurol Neurochir Pol"},{"key":"4860_CR135","doi-asserted-by":"publisher","DOI":"10.1523\/eneuro.0256-18.2018","author":"CL Limebeer","year":"2018","unstructured":"Limebeer CL, Rock EM, Sharkey KA, Parker LA (2018) Nausea-induced 5-HT release in the interoceptive insular cortex and regulation by monoacylglycerol lipase (MAGL) inhibition and cannabidiol. eNeuro. https:\/\/doi.org\/10.1523\/eneuro.0256-18.2018","journal-title":"eNeuro"},{"key":"4860_CR136","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1073\/pnas.0711278105","volume":"105","author":"JE Lauckner","year":"2008","unstructured":"Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Mackie K (2008) GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci U S A 105:2699\u20132704","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4860_CR137","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.664535","volume":"9","author":"Y Liu","year":"2021","unstructured":"Liu Y, Ouyang P, Zheng Y, Mi L, Zhao J, Ning Y, Guo W (2021) A selective review of the excitatory-inhibitory imbalance in schizophrenia: underlying biology, genetics, microcircuits, and symptoms. Front Cell Dev Biol 9:664535","journal-title":"Front Cell Dev Biol"},{"key":"4860_CR138","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.bbi.2019.06.009","volume":"81","author":"JP Nakamura","year":"2019","unstructured":"Nakamura JP, Schroeder A, Hudson M, Jones N, Gillespie B, Du X, Notaras M, Swaminathan V, Reay WR, Atkins JR, Green MJ, Carr VJ, Cairns MJ, Sundram S, Hill RA (2019) The maternal immune activation model uncovers a role for the Arx gene in GABAergic dysfunction in schizophrenia. Brain Behav Immun 81:161\u2013171","journal-title":"Brain Behav Immun"},{"key":"4860_CR139","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.biopsych.2024.11.015","volume":"98","author":"M Santoni","year":"2025","unstructured":"Santoni M, Pistis M (2025) Maternal immune activation and the endocannabinoid system: focus on two-hit models of schizophrenia. Biol Psychiatry 98:105\u2013115","journal-title":"Biol Psychiatry"},{"key":"4860_CR140","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.neuron.2023.01.018","volume":"111","author":"EC Rosenberg","year":"2023","unstructured":"Rosenberg EC, Chamberland S, Bazelot M, Nebet ER, Wang X, McKenzie S, Jain S, Greenhill S, Wilson M, Marley N, Salah A, Bailey S, Patra PH, Rose R, Chenouard N, Sun SD, Jones D, Buzs\u00e1ki G, Devinsky O, Woodhall G, Scharfman HE, Whalley BJ, Tsien RW (2023) Cannabidiol modulates excitatory-inhibitory ratio to counter hippocampal hyperactivity. Neuron 111:1282-1300.e1288","journal-title":"Neuron"},{"key":"4860_CR141","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2023.109715","volume":"240","author":"L Zhang","year":"2023","unstructured":"Zhang L, Lin C, Zhu J, He Y, Zhan M, Xia X, Yang N, Yang K, Wang B, Zhong Z, Wang Y, Ding W, Yang Y (2023) Restoring prefrontal cortical excitation-inhibition balance with cannabidiol ameliorates neurobehavioral abnormalities in a mouse model of neurodevelopmental disorders. Neuropharmacology 240:109715","journal-title":"Neuropharmacology"},{"key":"4860_CR142","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1176\/appi.ajp.2011.11010052","volume":"168","author":"AA Curley","year":"2011","unstructured":"Curley AA, Arion D, Volk DW, Asafu-Adjei JK, Sampson AR, Fish KN, Lewis DA (2011) Cortical deficits of glutamic acid decarboxylase 67 expression in schizophrenia: clinical, protein, and cell type-specific features. Am J Psychiatry 168:921\u2013929","journal-title":"Am J Psychiatry"},{"key":"4860_CR143","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1038\/npp.2015.117","volume":"40","author":"K Fujihara","year":"2015","unstructured":"Fujihara K, Miwa H, Kakizaki T, Kaneko R, Mikuni M, Tanahira C, Tamamaki N, Yanagawa Y (2015) Glutamate decarboxylase 67 deficiency in a subset of GABAergic neurons induces schizophrenia-related phenotypes. Neuropsychopharmacology 40:2475\u20132486","journal-title":"Neuropsychopharmacology"},{"key":"4860_CR144","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.neuropharm.2013.03.027","volume":"71","author":"MR Pazos","year":"2013","unstructured":"Pazos MR, Mohammed N, Lafuente H, Santos M, Mart\u00ednez-Pinilla E, Moreno E, Valdizan E, Romero J, Pazos A, Franco R, Hillard CJ, Alvarez FJ, Mart\u00ednez-Orgado J (2013) Mechanisms of cannabidiol neuroprotection in hypoxic\u2013ischemic newborn pigs: role of 5HT1A and CB2 receptors. Neuropharmacology 71:282\u2013291","journal-title":"Neuropharmacology"},{"key":"4860_CR145","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/bph.13368","volume":"173","author":"WH Hind","year":"2016","unstructured":"Hind WH, England TJ, O\u2019Sullivan SE (2016) Cannabidiol protects an <i>in vitro<\/i> model of the blood-brain barrier from oxygen-glucose deprivation via PPAR\u03b3 and 5-HT1A receptors. Br J Pharmacol 173:815\u2013825","journal-title":"Br J Pharmacol"},{"key":"4860_CR146","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2025.116742","volume":"233","author":"C Alexander","year":"2025","unstructured":"Alexander C, Jeon J, Nickerson K, Hassler S, Vasefi M (2025) CBD and the 5-HT1A receptor: a medicinal and pharmacological review. Biochem Pharmacol 233:116742","journal-title":"Biochem Pharmacol"},{"key":"4860_CR147","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.biopsych.2004.12.006","volume":"57","author":"DC D'Souza","year":"2005","unstructured":"D\u2019Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, Gueorguieva R, Cooper TB, Krystal JH (2005) Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 57:594\u2013608","journal-title":"Biol Psychiatry"},{"key":"4860_CR148","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s40263-020-00752-2","volume":"34","author":"JT Kantrowitz","year":"2020","unstructured":"Kantrowitz JT (2020) Targeting serotonin 5-HT2A receptors to better treat schizophrenia: rationale and current approaches. CNS Drugs 34:947\u2013959","journal-title":"CNS Drugs"},{"key":"4860_CR149","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2024.173879","volume":"245","author":"JFC Pedrazzi","year":"2024","unstructured":"Pedrazzi JFC, Silva-Amaral D, Issy AC, Gomes FV, Crippa JA, Guimar\u00e3es FS, Del Bel E (2024) Cannabidiol attenuates prepulse inhibition disruption by facilitating TRPV1 and 5-HT1A receptor-mediated neurotransmission. Pharmacol Biochem Behav 245:173879","journal-title":"Pharmacol Biochem Behav"},{"key":"4860_CR150","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/nn1288","volume":"7","author":"DS Choi","year":"2004","unstructured":"Choi DS, Cascini MG, Mailliard W, Young H, Paredes P, McMahon T, Diamond I, Bonci A, Messing RO (2004) The type 1 equilibrative nucleoside transporter regulates ethanol intoxication and preference. Nat Neurosci 7:855\u2013861","journal-title":"Nat Neurosci"},{"key":"4860_CR151","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s11064-005-6978-1","volume":"30","author":"EB Russo","year":"2005","unstructured":"Russo EB, Burnett A, Hall B, Parker KK (2005) Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 30:1037\u20131043","journal-title":"Neurochem Res"},{"key":"4860_CR152","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104749","volume":"156","author":"N Rodrigues da Silva","year":"2020","unstructured":"Rodrigues da Silva N, Gomes FV, Sonego AB, Silva NRD, Guimar\u00e3es FS (2020) Cannabidiol attenuates behavioral changes in a rodent model of schizophrenia through 5-HT1A, but not CB1 and CB2 receptors. Pharmacol Res 156:104749","journal-title":"Pharmacol Res"},{"key":"4860_CR153","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22010134","author":"E Galaj","year":"2020","unstructured":"Galaj E, Xi ZX (2020) Possible receptor mechanisms underlying cannabidiol effects on addictive-like behaviors in experimental animals. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22010134","journal-title":"Int J Mol Sci"},{"key":"4860_CR154","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1124\/jpet.109.162701","volume":"332","author":"JA Przybyla","year":"2010","unstructured":"Przybyla JA, Watts VJ (2010) Ligand-induced regulation and localization of cannabinoid CB1 and dopamine D2L receptor heterodimers. J Pharmacol Exp Ther 332:710\u2013719","journal-title":"J Pharmacol Exp Ther"},{"key":"4860_CR155","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s00213-021-05905-9","volume":"239","author":"E Chesney","year":"2022","unstructured":"Chesney E, Oliver D, McGuire P (2022) Cannabidiol (CBD) as a novel treatment in the early phases of psychosis. Psychopharmacology 239:1179\u20131190","journal-title":"Psychopharmacology"},{"key":"4860_CR156","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.bbr.2016.04.042","volume":"309","author":"AB Sonego","year":"2016","unstructured":"Sonego AB, Gomes FV, Del Bel EA, Guimaraes FS (2016) Cannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein expression in the dorsolateral striatum via 5-HT1A receptors in mice. Behav Brain Res 309:22\u201328","journal-title":"Behav Brain Res"},{"key":"4860_CR157","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.pnpbp.2013.06.005","volume":"46","author":"FV Gomes","year":"2013","unstructured":"Gomes FV, Del Bel EA, Guimar\u00e3es FS (2013) Cannabidiol attenuates catalepsy induced by distinct pharmacological mechanisms via 5-HT1A receptor activation in mice. Prog Neuropsychopharmacol Biol Psychiatry 46:43\u201347","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"4860_CR158","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.614811","volume":"12","author":"FM Leweke","year":"2021","unstructured":"Leweke FM, Rohleder C, Gerth CW, Hellmich M, Pukrop R, Koethe D (2021) Cannabidiol and amisulpride improve cognition in acute schizophrenia in an explorative, double-blind, active-controlled, randomized clinical trial. Front Pharmacol 12:614811","journal-title":"Front Pharmacol"},{"key":"4860_CR159","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.indcrop.2014.08.011","volume":"68","author":"EMJ Salentijn","year":"2015","unstructured":"Salentijn EMJ, Zhang Q, Amaducci S, Yang M, Trindade LM (2015) New developments in fiber hemp (Cannabis sativa L.) breeding. Ind Crops Prod 68:32\u201341","journal-title":"Ind Crops Prod"},{"key":"4860_CR160","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1017\/S0033291719003519","volume":"51","author":"A O'Neill","year":"2021","unstructured":"O\u2019Neill A, Wilson R, Blest-Hopley G, Annibale L, Colizzi M, Brammer M, Giampietro V, Bhattacharyya S (2021) Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis. Psychol Med 51:596\u2013606","journal-title":"Psychol Med"},{"key":"4860_CR161","doi-asserted-by":"publisher","first-page":"4732","DOI":"10.1017\/S0033291722001672","volume":"53","author":"B Gunasekera","year":"2023","unstructured":"Gunasekera B, Wilson R, O\u2019Neill A, Blest-Hopley G, O\u2019Daly O, Bhattacharyya S (2023) Cannabidiol attenuates insular activity during motivational salience processing in patients with early psychosis. Psychol Med 53:4732\u20134741","journal-title":"Psychol Med"},{"key":"4860_CR162","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-026-02249-3","author":"A Di Francesco","year":"2026","unstructured":"Di Francesco A, Cutrufelli P, Chiarenza C, Zambuto L, Concerto C, Mineo L, Petralia A, Catalfo M, Rodolico A, Samara M, Leucht S, Caraci F, Signorelli MS (2026) Cannabidiol for the treatment of positive and negative symptoms in schizophrenia spectrum disorders: a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. https:\/\/doi.org\/10.1007\/s00406-026-02249-3","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"4860_CR163","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291725101803","volume":"55","author":"Y Li","year":"2025","unstructured":"Li Y, Yu M, Yang H, Shi L, Wang T, He R, Liu K, Dong W, Liang X, Xiang B (2025) Efficacy of adjunctive antidepressants in treating negative symptoms of schizophrenia: a systematic review and network meta-analysis. Psychol Med 55:e317","journal-title":"Psychol Med"},{"key":"4860_CR164","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.2147\/NDT.S539306","volume":"21","author":"CU Correll","year":"2025","unstructured":"Correll CU, Mafi CE, Fagiolini A, Seerden P, Seifritz E, Tiihonen J, Vita A, Citrome L (2025) Brexpiprazole in the management of schizophrenia: a consensus report of best practices from acute to maintenance treatment. Neuropsychiatr Dis Treat 21:1857\u20131883","journal-title":"Neuropsychiatr Dis Treat"},{"key":"4860_CR165","doi-asserted-by":"publisher","first-page":"332","DOI":"10.2133\/dmpk.DMPK-12-RG-129","volume":"28","author":"R Jiang","year":"2013","unstructured":"Jiang R, Yamaori S, Okamoto Y, Yamamoto I, Watanabe K (2013) Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19. Drug Metab Pharmacokinet 28:332\u2013338","journal-title":"Drug Metab Pharmacokinet"},{"key":"4860_CR166","doi-asserted-by":"publisher","DOI":"10.3390\/biom15121668","author":"JH Na","year":"2025","unstructured":"Na JH, Lee YM (2025) Pharmacological and pharmacokinetic profile of cannabidiol in human epilepsy: a review of metabolism, therapeutic drug monitoring, and interactions with antiseizure medications. Biomolecules. https:\/\/doi.org\/10.3390\/biom15121668","journal-title":"Biomolecules"},{"key":"4860_CR167","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1007\/s11606-020-06504-8","volume":"36","author":"P Balachandran","year":"2021","unstructured":"Balachandran P, Elsohly M, Hill KP (2021) Cannabidiol interactions with medications, illicit substances, and alcohol: a comprehensive review. J Gen Intern Med 36:2074\u20132084","journal-title":"J Gen Intern Med"},{"key":"4860_CR168","unstructured":"WHO (2018) WHO Expert Committee on Drug Dependence: Fortieth report (WHO Technical Report Series, No. 1013). In. World Health Organization (Geneva, Switzerland), pp ISSN 0512\u20133054"}],"container-title":["Neurochemical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-026-04860-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11064-026-04860-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-026-04860-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T10:02:20Z","timestamp":1787824940000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11064-026-04860-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":168,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["4860"],"URL":"https:\/\/doi.org\/10.1007\/s11064-026-04860-1","relation":{},"ISSN":["0364-3190","1573-6903"],"issn-type":[{"value":"0364-3190","type":"print"},{"value":"1573-6903","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"assertion":[{"value":"8 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors confirm that this article content has no conflict of interest.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"251"}}